SUMMIT: tirzepatide in heart failure with preserved ejection fraction
Extending the evidence from weight and glucose into a difficult-to-treat form of heart failure.
A hard problem
Heart failure with preserved ejection fraction (HFpEF) is a common form of heart failure in which the heart pumps with normal ejection fraction but fills poorly. It is closely linked to obesity and has historically had few effective therapies, making it a high-priority research target.
Obesity-related HFpEF
SUMMIT enrolled adults with HFpEF and obesity and randomized them to tirzepatide or placebo. Endpoints included a composite of cardiovascular death or worsening heart-failure events and changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated symptom and quality-of-life score.
Fewer events, better symptoms
Tirzepatide reduced the risk of the composite endpoint and improved KCCQ scores compared with placebo, along with weight loss and reductions in inflammatory markers. The findings suggested benefit beyond what weight loss alone might predict, though mechanisms are still being studied.
A widening role
SUMMIT positioned tirzepatide as potentially relevant to a cardiometabolic condition with few options, part of a broader shift in which incretin therapies are studied for organ-specific outcomes — heart, liver, sleep — not only weight and glucose.
Caveats
Heart failure care is specialist-led and individualized; this is not a treatment recommendation. The branded product was studied. Compounded tirzepatide is not FDA-approved.
Benefit beyond weight loss?
A recurring question with SUMMIT is whether the benefits simply reflect weight loss or represent effects beyond it. The trial reported reductions in inflammatory markers and improvements in symptoms and events that some researchers argue exceed what weight loss alone would predict, hinting at additional mechanisms — possibly effects on inflammation, fluid handling or the heart and vasculature directly. The honest answer is that disentangling “weight-mediated” from “weight-independent” effects is genuinely difficult, and the science is not settled. What is clearer is the clinical signal: in a form of heart failure with historically few options, an obesity-directed therapy improved meaningful outcomes. That is significant for a patient group that has been hard to help. As with every indication discussed here, heart-failure management is specialist-led and individualized, and this evidence informs rather than dictates care. Readers wanting the precise endpoints and effect sizes should consult the primary publication, since summaries necessarily simplify a nuanced trial.
Primary sources
- Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.
- U.S. Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information. Eli Lilly and Company.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
Common questions
What did SUMMIT find?
In adults with obesity-related HFpEF, tirzepatide reduced a composite of cardiovascular death and worsening heart-failure events and improved symptom scores versus placebo.
Is tirzepatide a heart failure drug?
SUMMIT studied it specifically in obesity-related HFpEF with positive results, but heart failure treatment is specialist-led and individualized.
What is HFpEF?
Heart failure with preserved ejection fraction — the heart pumps normally but fills poorly. It's strongly linked to obesity and historically hard to treat.